Recent News

• 01.29.2026 - Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
• 01.29.2026 - Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Recent Filings

• 01.28.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.23.2026 - 8-K Current report
• 01.09.2026 - EX-99.1 EX-99.1
• 01.09.2026 - 8-K Current report
• 12.30.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.29.2025 - D Notice of Exempt Offering of Securities
• 12.29.2025 - EFFECT Notice of Effectiveness
• 12.19.2025 - S-3 Registration statement under Securities Act of 1933
• 12.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.11.2025 - 4 Statement of changes in beneficial ownership of securities